hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases
Texas Tech University, Lubbock, USA.
Southern Medical University, Guangzhou, China; Karolinska Institute, Stockholm, Sweden.ORCID iD: 0000-0001-7790-8197
2018 (English)In: Trends in Biotechnology, ISSN 0167-7799, E-ISSN 1879-3096, Vol. 36, no 7, p. 686-699Article, review/survey (Refereed) Published
Abstract [en]

The prevalence of autoimmune disorders is increasing steadily and there is no permanent cure available. Immunomodulation through repeated exposure of antigens, known as antigen-specific immune tolerance or antigen-specific immunotherapy (ASI), is a promising approach to treat or prevent autoimmune disorders. Different optimization protocols (immunization routes, delivery systems, and approaches) are being developed to implement ASI against self-proteins. Including appropriate adjuvants, altered peptide ligand, and using multipeptides are approaches that can be used to specifically target autoimmunity. This review explores various ASI application methods, including different routes of antigen-specific sensitization, delivery systems, immunomodulators containing specific antigens, and other targeted approaches that have been successfully demonstrated to have therapeutic effects on autoimmune diseases. © 2018 Elsevier Ltd.

Place, publisher, year, edition, pages
Cambridge, MA: Elsevier, 2018. Vol. 36, no 7, p. 686-699
Keywords [en]
antigen delivery systems, antigen-specific immune tolerance, autoimmune diseases, routes of administration
National Category
Rheumatology and Autoimmunity Biomaterials Science
Identifiers
URN: urn:nbn:se:hh:diva-48387DOI: 10.1016/j.tibtech.2018.02.008ISI: 000435199500008PubMedID: 29588069Scopus ID: 2-s2.0-85044331253OAI: oai:DiVA.org:hh-48387DiVA, id: diva2:1703100
Note

KSN received funds for his research (C1034211) from Southern Medical University, Guangzhou, China. 

Available from: 2022-10-12 Created: 2022-10-12 Last updated: 2023-02-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nandakumar, Kutty Selva

Search in DiVA

By author/editor
Nandakumar, Kutty Selva
In the same journal
Trends in Biotechnology
Rheumatology and AutoimmunityBiomaterials Science

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 20 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf